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INTRODUCTION
•   Prophylaxis with replacement factor VIII (FVIII) is the standard of care for people with 
hemophilia A, and is known to reduce the frequency of bleeding episodes and prevent 
arthropathy1
•   However, despite prophylactic factor replacement, patients may still be at risk for 
developing bleeding episodes2
•   The Phase 3 A-LONG study demonstrated the prolonged half-life of recombinant factor 
VIII Fc fusion protein (rFVIIIFc; geometric mean, 19.0 hours) relative to recombinant 
FVIII (rFVIII; geometric mean, 12.4 hours), and the efficacy and safety of rFVIIIFc for 
routine prophylaxis and treatment of bleeding in people with severe hemophilia A3
•   In the A-LONG study (including participants receiving either episodic or prophylactic 
treatment with rFVIIIFc), most acute bleeding episodes were resolved with a single 
rFVIIIFc infusion (87.3%), and the majority of participants rated their response to 
treatment as “excellent” or “good” (77.6%)3
 –  A subanalysis of the efficacy of rFVIIIFc for the treatment of bleeding only in subjects 
receiving rFVIIIFc prophylaxis has not been performed to date 
 –  The magnitude of the peak factor activity following treatment of a bleeding episode 
and/or scheduled prophylaxis in subjects receiving rFVIIIFc prophylaxis has not yet 
been evaluated
OBJECTIVES
•   The purpose of this post hoc analysis was to assess the efficacy of rFVIIIFc used for the 
treatment of bleeding in participants who received rFVIIIFc prophylaxis in the A-LONG 
study 
•   In addition, a population pharmacokinetic model of rFVIIIFc was used to predict FVIII 
activity in participants who use rFVIIIFc to treat bleeding episodes in close proximity to 
their next scheduled prophylaxis dose 
METHODS
Study Design and Participants
•   The A-LONG study was a Phase 3, open-label, multicenter, partially randomized study 
(ClinicalTrials.gov Identifier: NCT01181128)
•   This study included male participants ≥12 years of age with severe hemophilia A  
(<1 IU/dL [1%] endogenous FVIII activity or severe genotype) who had been previously 
treated prophylactically, or episodically with ≥12 bleeding events in the 12 months prior 
to the study; participants with a history of inhibitors were excluded
 –  Participants were enrolled into 1 of 3 treatment groups: individualized prophylaxis 
(twice-weekly rFVIIIFc dosing; 25 IU/kg on Day 1 and 50 IU/kg on Day 4 to start, 
followed by 25–65 IU/kg every 3–5 days to maintain trough levels between 1–3 IU/dL), 
weekly prophylaxis (65 IU/kg rFVIIIFc once weekly), or episodic treatment  
(10–50 IU/kg rFVIIIFc as needed for the treatment of bleeding episodes) 
 ∙  This analysis included only participants in A-LONG who received rFVIIIFc 
prophylaxis (enrolled in the individualized prophylaxis or weekly prophylaxis 
groups) 
•   Acute bleeding episodes were treated with 10 to 50 IU/kg of rFVIIIFc; dosing was based 
on the participant’s clinical condition, type and severity of the bleeding event, and the 
participant’s previous dosing history for a similar bleeding episode (Table 1)
Outcomes
•   Outcomes evaluated in this analysis included: number of bleeding episodes, location 
and type of bleeds, the average dose per infusion required to treat a bleed, the number 
of infusions required to resolve a bleed, participants’ assessment of response to 
treatment (recorded within 8–12 hours of first infusion), and safety  
Statistics
•   Descriptive statistics were used to provide the median and interquartile range (IQR). 
Frequency and percent were summarized categorically 
Pharmacokinetic Simulations
•   A previously validated 2-compartment population pharmacokinetic model of rFVIIIFc,4 
developed based on activity-time profiles from participants enrolled in the Phase 1/2a 
study of rFVIIIFc (n = 16)5 and the A-LONG study (n = 164),3 was used to predict FVIII 
activity levels in 1,000 hypothetical patients 
•   FVIII activity was modeled under 2 scenarios in which a 25 IU/kg dose of rFVIIIFc was 
used to treat a bleeding episode 24 hours before a scheduled prophylactic dose for 
patients at steady state on a regimen of 50 IU/kg every 3 or 4 days
 –  A dose of 25 IU/kg was selected to approximate the median dose per infusion used to 
treat a bleed
 –  Twenty-four hours is likely to be the closest proximity to a scheduled prophylaxis 
dose that a separate dose would be used to treat a bleeding episode
 –  The median total weekly prophylactic dose in Arm 1 of the A-LONG study was  
77.9 IU/kg.3  For this modeling exercise, the dose and intervals used were chosen 
because 50 IU/kg was one of the starting doses in A-LONG, 4 days was one of the 
starting interval lengths, and 3 days was the shortest interval used in A-LONG
RESULTS
Study Population
•   Demographic and baseline characteristics in this study population were representative 
of a population with severe hemophilia A (Table 2).  Additionally, most participants 
in the individualized prophylaxis and weekly prophylaxis groups reported similar or 
increased physical activity with the use of rFVIIIFc on-study
Bleeding Episodes by Type and Location
•   In the individualized prophylaxis group, 209 bleeding episodes were reported in  
64 participants (median annualized bleeding rate [ABR], 1.6; median spontaneous  
ABR, 0.0) 
 –  Of these, 119 were spontaneous and 87 were traumatic bleeds (for 3 bleeds, the type 
of bleed is unknown) 
 – The location of bleeding episodes is shown in Figure 1A
•   In the weekly prophylaxis group, 92 bleeding episodes were reported in 19 participants 
(median ABR, 3.59; median spontaneous ABR, 1.93) 
 – Of these, 60 were spontaneous and 32 were traumatic bleeds 
 – The location of bleeding episodes is shown in Figure 1B
Treatment of Bleeding
•   The majority of bleeding episodes were resolved with 1 or 2 rFVIIIFc infusions in the 
individualized prophylaxis and weekly prophylaxis groups (Figure 2) 
•   The median number of infusions of rFVIIIFc required to resolve a bleeding episode was 
1.0 in both the individualized prophylaxis and weekly prophylaxis groups
•   The median (IQR) dose per infusion required to resolve bleeding episodes was similar 
in both treatment groups (Figure 3)
•   When evaluating their response to rFVIIIFc for the treatment of a bleeding episode, 
78.8% and 64.8% of participants in the individualized prophylaxis and weekly 
prophylaxis groups, respectively, rated their response as either “excellent” or “good” 
(Figure 4) 
Safety 
•   rFVIIIFc was generally well tolerated and no serious vascular thrombotic events were 
reported
•   No inhibitors were detected in any participant with an evaluable inhibitor test
Population Pharmacokinetic Simulations of the Treatment of Bleeding  
With rFVIIIFc
•   Population pharmacokinetic simulations predicted that the majority of patients on 
prophylaxis who use rFVIIIFc to treat a bleeding episode in close proximity to their next 
scheduled prophylactic dose will have maximum factor activity levels that fall within the 
normal range (Figure 5) 
CONCLUSIONS
•   Bleeding episodes among participants in the prophylaxis arms of the A-LONG study 
were rare 
•   rFVIIIFc was safe and effective when used to treat bleeding episodes in participants 
receiving routine prophylaxis, with most bleeds resolving with 1 or 2 rFVIIIFc 
infusions; efficacy for treatment of bleeding in the prophylaxis arms was consistent 
with that in the episodic treatment arm
•   Clinical observations during A-LONG indicate that the maximal plasma factor 
activity level is reached immediately following infusion of rFVIIIFc.  Population 
pharmacokinetic simulations demonstrate that predicted maximum FVIII activity 
levels are likely to fall within the normal range for a majority of patients using 
rFVIIIFc prophylaxis when a bleeding event is treated in close proximity to a 
scheduled prophylaxis dose
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Table 1.  Recommended rFVIIIFc Dosing by Bleeding Episode Severitya
Bleeding episode severity rFVIIIFc dose
Minor 10–20 IU/kg
Moderate to severe 15–30 IU/kg
Major to life threatening
40–50 IU/kg initial dose followed by
20–25 IU/kg every 12–24 hours until 
bleeding episode resolved
a If a bleeding episode occurred or was ongoing at the time a prophylactic dose of rFVIIIFc was scheduled, the participant  
was to treat the bleeding episode using a dose no less than his regular prophylaxis dose.
Table 2.  Demographic and Baseline Characteristics
Individualized  
prophylaxis group 
(n = 118)
Weekly 
prophylaxis group 
(n = 24)
Age, y, median (range) 29 (12–65) 31.5 (18–59)
Weight, kg, median (range) 71.65 (42.0–127.4) 75.85 (50.0–105.0)
Race, n (%)a
   White
   Black
   Asian
   Other
79 (66.9)
7 (5.9)
27 (22.9)
5 (4.2)
12 (50.0)
1 (4.2)
11 (45.8)
0
Geographic location, n (%)
   Europe
   North America
   Otherb
34 (28.8)
44 (37.3)
40 (33.9)
3 (12.5)
5 (20.8)
16 (66.7)
Prestudy FVIII regimen, n (%)
   Prophylaxis
   Episodic treatment
87 (73.7)
31 (26.3)
0
24 (100)
Estimated bleeding events in prior  
12 months, median (IQR)c
   Prior prophylaxis
   Prior episodic treatment
6.0 (2–15)
27 (17–41)
−
29.5 (19–44)
1 or more target joint, n (%)
   Prior prophylaxis
   Prior episodic treatment
47 (39.8)
26 (22.0)
−
22 (91.7)
aPercentages may not total 100.0% due to rounding. 
bOther included Australia, New Zealand, Brazil, Hong Kong, India, Japan, Russia, and South Africa.
cCalculation was based on available data.
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Figure 2.  Percentage of bleeding episodes resolved with 1 or 1–2 rFVIIIFc infusions. 
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Figure 4.  Participants’ assessment of response to treatment for all infusions.a 
aRecorded within 8 to 12 hours of first infusion.
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Figure 5.  Predicted FVIII activity versus time profiles when a bleeding episode is 
treated with rFVIIIFc (25 IU/kg, regardless of prophylaxis dosing regimen) 24 hours 
before a scheduled prophylactic dose.a,b  
Cmax = maximum concentration; PI = prediction interval.
a Based on the incremental recovery observed in A-LONG, a rFVIIIFc dose of 25 IU/kg is expected to increase factor activity  
by approximately 50 IU/dL.
b The median time to 1% with a single dose of rFVIIIFc 50 IU/kg is 4.9 days.3  At steady state, a prophylaxis regimen of rFVIIIFc 
50 IU/kg every 3 days would be predicted to maintain 89.4% of individuals above 1%, and a prophylaxis regimen of rFVIIIFc 
50 IU/kg every 4 days would be predicted to maintain 67.2% of individuals above 1%.6  
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Figure 1.  Bleeding episodes by location.a
aA single bleeding episode could have been reported in ≥1 location.
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Figure 3.  Median (IQR) dose per infusion and total dose (IU/kg) of rFVIIIFc required 
to resolve a bleeding episode.
